Long-term use of burosumab for the treatment of tumor-induced osteomalacia

• Published in: Osteoporosis international 2023-01, Vol.34 (1), p.201-206
• Main Authors: Crotti, C., Zucchi, F., Alfieri, C., Caporali, R., Varenna, M.
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal, Humanized - therapeutic use; COVID-19; COVID-19 - complications; Endocrinology; Female; Fibroblast growth factor 23; Fibroblast Growth Factors; Fractures; Humans; Hypophosphatemia; Hypophosphatemia - drug therapy; Hypophosphatemia - etiology; Hypophosphatemia - pathology; Medical treatment; Medicine; Medicine & Public Health; Middle Aged; Monoclonal antibodies; Orthopedics; Osteomalacia; Osteomalacia - drug therapy; Osteomalacia - etiology; Paraneoplastic syndrome; Paraneoplastic Syndromes - drug therapy; Paraneoplastic Syndromes - etiology; Patients; Phosphates; Phosphorus; Rheumatology; Sacrum; Short Communication; Surgery; Tumors
• ISSN: 0937-941X; 1433-2965
• DOI: 10.1007/s00198-022-06516-6

Summary Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by tumoral overproduction of FGF-23. Due to local recurrence, we describe the long-term efficacy and safety profile of burosumab, an anti-FGF-23 monoclonal antibody, in a TIO patient after three unsuccessfully surgical attempts. Introduction TIO is a rare paraneoplastic syndrome caused by tumoral overproduction of fibroblast growth factor 23 (FGF23), resulting in hyperphospaturia, hypophosphatemia, and osteomalacia. Surgery is the only definitive treatment, but tumor can locally recur, even after years from primary surgery. Furthermore, some tumors cannot be removed by surgery due to their location. Methods We describe the case of a 54-year-old woman affected by recurrent TIO who, after three unsuccessful surgical attempts of tumor removal, was treated with burosumab, an anti-FGF-23 monoclonal antibody. Results The patient was referred to our Bone Unit after experiencing several fractures in different sites, both traumatic and non-traumatic. At the time of first evaluation, at the age of 46, serum-phosphate (SP) was 1.2 mg/dL (reference range (RR) 2.5–4.5), 24-h urinary phosphate was 842 mg (RR 400–1000), and intact-FGF-23 was 117 pg/mL (RR 25–45). Imaging showed a metabolic pre-sacral lesion that firstly underwent to exploratory laparotomy. Then, patient underwent to surgical excision of tumor. After 18 months of well-being, tumor relapsed and even the subsequent surgery was not able to completely remove it. Since 2015, patient was maintained in phosphorus supplements and 1,25(OH) 2 vitamin D 3 , but SP levels never normalized. In September 2019, she was started on burosumab, initially at the dose of 0.3 mg/kg/month, progressively increased to the current 0.8 mg/kg/month, with great improvement of pain, physical performance, and normalization of SP levels. Burosumab was temporary and cautionary discontinued for COVID-19 pneumonia, with a worsening of SP. After restart of burosumab, biochemistry returned to normal. Conclusions To our knowledge, this is the first European patient affected by TIO treated with burosumab for more than 2 years. Burosumab is a promising therapy in the medical treatment of TIO refractory or not eligible for definitive surgery, with good efficacy and safety profile.